5 курс / Инфекционные болезни / Доп. материалы / Диссертация_Скворцова_Е_С_Инфильтративный_туберкулез_легких,_язвенная

74. Blumberg H.M., Burman W.J., Chaisson R.E. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis //Am J Respir Crit Care Med. – 2003. - 167. – Р.603-662.

75.Boehme C.C., Nabeta P., Hilleman D. et al. Rapid molecular detection of tuberculosis and rifampin resistance //N. Engl. J. Med. – 2010; Sep 9. – Vol. 363(11). – Р.1005-1015.

76.Boyle B.A. Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part I //AIDS Read. – 2001. – Vol.11(7).

–Р.354-363.

77.Burman W.J., Jones B.E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy //Am. J. Respir. Crit. Care. Med. – 2001. –

Vol.164. – Р. 7-12.

78.Cattamanchi A., Davis J.L., Worodria W. et al. Sensitivity and specificity of fluorescence microscopy for diagnosing pulmonary tuberculosis in a high HIV prevalence setting //Int J Tuberc Lung Dis. – 2009. – Vol.13. – Р.11301136.

79.Charalambous S., Grant A.D., Innes C. et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme // AIDS. – 2010 Nov. – Vol.24(5). – S5-13.

80.Cianci R., Montalto M., Pandolfi F. et al. Third-line rescue therapy for Helicobacter pylori infection // World J Gastroenterol. - 2006 April 21. –

Vol.12(15). – Vol.2313-2319.

81.Coker R., McKee M., Atun R. et al. Risk factors for pulmonary tuberculosis in Russia: case-control study //BMJ. – 2006. – Vol. 332. – Р. 85-87.

82.CorbettE.L., MarstonB., ChurchyardG.J. et al. Tuberculosis in subSaharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment //Lancet. – 2006. – Vol.367. – Р.926-37.

141

83.EACS Guidelines. European AIDS Clinical Society: Clinical management and treatment of HIV infected adults in Europe (Version 5-4, November 2009).www.europeanaidsclinicalsociety.org.

84.Eker B., Ortmann J., Migliori G.B. et al. Multidrug – and extensively drug-resistant tuberculosis. Germany//Emerg Infect Dis. – 2008. – Vol.14. –

Р.1700-1706.

85.El'kin, A.V., Repin I.M., LevashevI.N.Outcomes of surgical treatment of surgical treatment of patients with progressive pulmonary tuberculosis an diseases // Probl Tuberk Bolezn Legk. – 2005. – Vol.11. – Р.22-5.

86.El-Sadr W.M., Perlman D.C., Denning E. et al. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes //Clin. Infect. Dis. – 2001. – № 32(4). – Р.623-632.

87.Fennerty M.B., Sampliner R.E., McGee D.L. et al. Intestinal metaplasia of the stomach: identification by a selective mucosal staining technique

//Gastrointest Endosc. – 1992. – Vol.38. – Р.696-8.

88.Friedland G., Churchyard G.J., Nardell E. Tuberculosis and HIV Coinfection: Current State of Knowledge and Research Priorities //J Infect Dis. –

2007. – Vol. 196(1). –P.1-3.

89.Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa //Lancet. – 2006.

–Vol.368. – Р.1575-80.

90.Gandhi N.R., Shav N.S., Andrews J.R. et al. Tugella Ferry Care and Research (TF CARES) Collaboration. HIV coinfection in multidrug – and extensively drug resistant tuberculosis results in high early mortality //Am J Respir Crit Care Med. – 2010 Jan 1. – Vol. 181(1). – Р.80-86.

91.Goletti D., Weissman D., Jackson R.W. et al. Effect of Mycobacterium tuberculosis on HIV-replication. Role of immune activation.

/Immunol. - 1996 Aug l. – Vol.157(3):1271-8.

142

92.Grant A.D., Charalambous S., Fielding K.L. et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study //JAMA. – 2005.

–Vol.293. – Р.2719-2725.

93.Girardi E., Antonucci G., Vanacore P. et al. Tuberculosis in HIVinfected persons in the context of wide availability of highly active antiretroviral therapy //Eur. Respir. J. – 2004. – №24(1). – Р. 11-17.

94.Gisbert J.P., Calvet X.Helicobacter pylori-negative Duodenal Ulcer //Disease Aliment Pharmacol Ther. – 2009. – Vol.30(8). – Р.791-815.

95.Havlir D., Ive P., Kendall M. et al. International Randomized Trial of Immediate vs Early ART in HIV+ Patients Treated for TB: ACTG 5221 STRIDE Study. Abstract 38, 18th CROI 2011, Boston.

96.Hobsley M., Tovey F.I., Holton J. Controversies in the Helicobacter pylori/duodenal ulcer story //Trans. R Soc Trop Med Hyg. – 2008. – Vol. 102. –

Р. 1171-75.

97.Hung C.C., Chen M.Y., Hsiao C.F. et al. Improved outcomes of HIV- 1-infected adults with tuberculosis in the era of highly active antiretroviral therapy // Aids. – 2003. – Vol.17. – P.2615-2622.

98.Karim S.A., Naidoo K., Grobler A. et al. Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trial in TB/HIV-co-infected patients in South Africa / //16-th CROI. –

Montreal_Canada, 2009. – Abst. 36a.

99.Karnofsky D.A., Burchenal J.H. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press, 1949:196.

100.KasaharaY., TuderR.M., Taraseviciene-Stewart L. et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema /J. Clin. Invest. - 2000.

–Vol.106(11): 1311–1319.

101.Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus

deferred antiretroviral therapy for HIV on survival //N Engl J Med. 2009 Apr 1.

143

102.Lange C., Lederman M.M., Nedvic K. et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection //AIDS. – 2003. – Vol. 17. – Р.20152023.

103.Lawn S.D., Bekker L.G, Wood R. et al. How effective does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control //AIDS. – 2005. – Vol.19. – Р.1113-1124.

104.Lawn S.D., Wilkinson R.G., Lipman M.C. et al. Immune

reconstitution and «unmasking» of tuberculosis during antiretroviral therapy // Am.

J.Respir Crit Care Med. – 2008. – Vol.177. – Р.680-685.

105.Lawn S.D., Török M.E., Wood R. Optimum time to start antiretroviral

therapy during HIV-associated opportunistic infections //Curr Opin Infect Dis. -

2011. – Vol. 24. – Р.34–42.

106.Leidl L., Mayanja-Kizza H., Sotgium G. et al. Relationship of immunodiagnostic assays for tuberculosis and number of circulating CD4+ T-cells in HIV-infection //Eur Respir J. – 2010. – Vol.35. – Р.619-626.

107.Mack U., Migliori G.B., Sester M. et al. LTBI: Latent tuberculosis infection or lasting immune response to Mycobacterium tuberculosis. A TBNET consensus statement //Eur Respir J. – 2009. – Vol.33. – Р.956-973.

108.Makadzange A., Ndhlovu C., Tkarinda C. et al. Early vs delayed ART in the treatment of cryptococcal meningitis in Africa. 36c, 16th CROI 2009,

Montréa.

109.Malfertheiner P., Megraud F., O Morain C.A., et al.Диагностика и лечение инфекции Helicobacterpylori – отчет согласительной конференции Маастрихт IV/ Флоренция //Вестник практического врача. – 2012. – С.6-22.

110.McGregor M.M., Olliaro P., Wolmarans L. et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis //Am J Respir Crit Care Med. – 1996. – Vol.154. – Р.1462-1467.

111.Metcalfe J.Z., Porco T.C., Westenhouse J. et al. Tuberculosis and HIV

Co-infection, California, USA, 1993–2008 / Emerging Infectious Diseases • www

144

.cdc.gov/eid • Vol. 19, No. 3, March 2013.– Р.400-406.

37. Meucci G., Di Battista R., Abbiati C., et al. Prevalence and risk factors of Helicobacter pylori-negative peptic ulcer: a multicenter study // J Clin Gastroenterol. - 2000 Jul. – Vol.31(1). – Р.42-47.

112.Meintjes G., Lawn S.D., Scano F. et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings //Lancet Infect Dis. – 2008. – Vol.8. – Р.516-523.

113.Meintjes G., Wilkinson R.G., Moroni C. et al. Randomized placebocontrolled trial of prednisolone for paradoxal tuberculosis-associated immune reconstitution inflammatory syndrome //AIDS. – 2010. – Vol.24. – Р.2381-2390.

114.Migliori G.B., Eker B., Richardson M.D. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis //Eur Respir J. – 2009. – Vol.34. – Р.2381-2390.

115.Murray J., Sonnenberg P., Shearer S.C. et al.Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients //Am. J. Respir. Crit. Care Med. –

1999. – Vol. 159 (3). – Р. 733-740.

116.Nambuya A., Sewankambo N., Migerwa J. et al. . Tuberculosis lymphadenitis among persons infected with human immunodeficiency virus (HIV) in Uganda //J. Clin. Pathol. – 1988. – № 41. – Р. 93-96.

117.Nishizawa T., Suzuki H., Matsuzaki J. et al. Helicobacter pylori Resistance to Rifabutin in the Last 7 Years //Antimicrob. Agents Chemother.

November 2011;55:11 5374-5375 published ahead of print 6 September 2011 doi:10.1128/AAC.05437-11.

118. Normark S., Nilsson C., Normark B.H. et al. Persistent infection with Helicobacter pylori and the development of gastric cancer // Adv. Cancer Res. – 2003. – Vol. 90. – P. 63–89.

119. OARAC 2011. DNNS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Offise of AIDS Research Advisory

Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1- 145

Aidsinfo.nih.gov/contenfiles/AdultandAdolescentGL.pdf.

120.Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.

121.Page K.R., Chaisson R., Godfrey-Faussett P. Tuberculosis-HIV Coinfection: Epidemiology, Clinical Aspects, and Interventions //In: Reichman and

Hershfield’s Tuberculosis. Third Edition, Part A/ed by M.Raviglione, Informa

healthcare, New York. – 2006. - Р.371-416.

122.Palella F.J.Jr., Deloria-Knoll M., Chmiel J.S. et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata //Ann Intern Med. - 2003. – Vol.138. – Р.620-626.

123.Perri F., Festa V., Clemente R. et al. Randomized study of two

‘rescue’ therapies for Helicobacter pylori-infected patients after failure of standard

triple therapies //AmJ Gastroenterol. – 2001. – Vol. 96. – Р. 58-6.

124.Philippou N., Roussos1 A., Tsimpoukas1 F. et al. Helicobacter pylori infection in patients with active pulmonary tuberculosis before the initiation of antituberculosis treatment // Annals Of Gastroenterology. – 2003. – Vol. 16(1). –

Р.49-52.

125.Powderly W.G., Saag M.S., Chapman S. et al. Predictors of optimal virological response to potent ART: AIDS. – 1999. – Vol.13. – Р.1873-1880.

126.Prego V., Glatt A.E., Roy V. et al. Comparative yield of blood culture for founded mycobacteria, liver biopsy and bone marrow biopsy in the diagnosis of fever of intertermined origin in HIV-infected patients //Arch. Intern. Med. – 1999.

–№ 150. – Р. 333-336.

127.Rachow A., Zumla A., Heinrich N. Et al. Rapid and accurate detection of mycobacterium tuberculosis in sputum samples by Cepheid xpert MTB/RIF assay-A clinical validation study //plos One. – 2011. – Vol.6. – e20458.

128.Rajabalinia H., Ghobakhlou M., Nikpour S., et al.Non-Helicobacter

pylori, non-nsaids peptic ulcers: a descriptive study on patients referred to 146

Taleghani hospital with upper gastrointestinal bleeding //Gastroenterol Hepatol Bed Bench. – 2012. – Vol. 5(4). – Р.190-196.

126. Reshetnikov O.V., Kurilovich S.A., Denisova D.V. et al. Prevalence of dyspepsia and irritable bowel syndrome among adolescents of Novosibirsk, western Siberia // Int J Circumpolar Health. - 2001 Apr. – Vol.60(2). – Р.253-7.

129.Rieder H.L., Zwahlen M., Zimmermann H. Mortality from respiratory tuberculosis in Switzerland // Soz. Präventivmed. – 1998. – Vol. 43. – Р. 162-6.

130.Ruiz M., Villasante F., Leon F. Et al. Dyspepsia-related quality of life. Spanish adaptation and validation of the questionnaire Dyspepsia-Related Health Scale // Med. Clin. (Barc). - 2001. - Vol. 117 (15). - P. 567-573.

131.Ruiz-Navarro M.D., Espinosa J.A., Hernandez M.J. et al. Effects of HIV status and other variables on the outcome of tuberculosis treatment in Spain //Arch. Bronconeumol. – 2005. – № 41(7). – Р. 363-370.

132.Sanaka M., Kuyama Y., Iwasaki. M. et al. No difference in seroprevalences of Helicobacter pylori infection between patients with pulmonary tuberculosis and those without //J Clin Gastroenterol. –1998. – Vol. 27. – Р. 331334.

133.Schwander S., Rusch-Gerdes S., Mateega A., et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis //Tuber Lung Dis. – 1995. – Vol.76. – Р.210-218.

134.Sharma M.P., Ahuja V. Current Management of Acid Peptic Disorders //JIACM. – 2003. – Vol. 4(3). – Р.228-33.

135.Shirin H., Leja M., Niv Y. Helicobacter pylori and non-malignant diseases // Helicobacter. – 2008. – Vol. 13(1). – Р. 23–27.

136.Severe P., Juste M.A., Ambroise A. et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti // N Engl J Med. – 2010. –

Vol. 363. – Р. 257–265.

147

137.Teves P.M., Ventura S.S., Salgado E.M. Characteristics of gastroduodenal ulcers in patients with negative biopsies for Helicobacter pylori // Acta Gastroenterol Latinoam. – 2010, Mar. – Vol. 40(1). – Р.40-5.

138.Thwe M., Maung W., Par P. et al. Epidemiological, clinical, biological characteristics and treatment outcomes of a cohort of HIV-TB patients enrolled in the integrated HIV care for tuberculosis patients program (IHC) in Mandalay, Myanmar //XVII International AIDS Conference. – Mexico City, Mexico. – 2008.

–№ MOPDB203.

139.Tjärnlund A. Does IgA play a role in protection against pulmonary

tuberculosis? // Licentiate thesis from the Department of Immunology Wenner-

Gren Institute, Stockholm University, Sweden. – 2005. – 58 р.

140.Torok M.E. Randomized controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis //Abstract H-1224, 49th ICAAC 2009, San Francisco.

141.Tsang K.W., Lam S.K. Extragastroduodenal conditions Associated with Helicobacter pylori Infection // HKMJ. – 1999, June – Vol. 5(2). – Р.169-174.

142.UNAIDS 2010. Global report: UNAIDS report on the global AIDS epidemic 2010. www.unaids.org/globalReport_full_en.pdf.

143.Velasco M., Castilla V., Sanz J. et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis //J. Acquir. Immune. Defic. Syndr. – 2009. – Vol. 50(2). – Р.148-152.

144.Weisfeld-Adams E., Andrzejewski A. Hunger and Poverty: Definitions and Distinctions, April 22, 2008.

145.Whalen C, Horsburgh CR, Horn D. et al. Accelerated course of human immunodeficiency virus infection after tuberculosis //Am. Respir. Crit. Care. Med.

-1995 Jan. – Vol. 151(l). – Р.129-35.

146.Wong W.M., Gu Q., Lam S.K. et al. Randomized controlled study of rabeprazole, levofl oxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pyloriinfection //Aliment Pharmacol Ther. –

2003. – Vol.17. – Р.553-560

148

147.World Health Organization. AntiMtuberculosis drug resistance in the world Report No. 2 Prevalence and trends: the WHO/IUATLD global project on antiMtuberculosis drug resistance surveillance, WHO, Geneva, 2000.

148.WHO report 2010. Global Tuberculosis control: WHO report 2010 /WHO. – Geneva, 2010. – 218 p.

149.Yokoyama T., Sato R., Rikimaru T. et al. Tuberculosis associated with gastrectomy // J. Infect. Chemother. 2004. - Vol. 10(5).-P. 299-302.

150.Zolopa A., Andersen J., Powderly W. et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial // PLoS. – 2009. – Vol.4. - e5575.

149